截至2025年8月22日收盘，惠泰医疗（688617）报收于280.59元，较上周的297.42元下跌5.66%。本周，惠泰医疗8月18日盘中最高价报298.97元。8 月22日盘中最低价报272.23元。惠泰医疗当前最新总市值395.67亿元，在医疗器械板块市值排名4/126，在两市A股市值排名425/5152。 本周关注点 股本股东变化 关于与关联方共同投资暨关联交易的公告 深圳惠泰医疗器械股份有限公司与关联方成正辉先生、上海惠深创业投资中心（有限合伙）、上海惠圳创业投资中心（有限合伙）共同对上海栗 亮医疗科技有限公司进行投资。惠泰医疗投资500万元，持股4.00%；成正辉投资600万元，持股4.80%；上海惠深及上海惠圳各投资200万元，分 别持股1.60%。合计投资1500万元，栗亮医疗整体投前估值为11000万元。栗亮医疗主要产品静脉胶处于研发阶段，尚未实现商业化，但其在国内 NBCA技术路径具备技术优势，处于临床审批领先梯队。栗亮医疗注册资本100万元，实收资本40万元，注册地址位于上海市浦东新区。截至2025 年6月30日，栗亮医疗资产总额1137482.86元，负债总额16561252.09元 ...

Company Updates - A major shareholder, Otsuka Pharmaceutical, has proposed a share sale plan, with buyers including Shanghai Shendi Group, We'Tron Capital Limited, and the company's management investment platform [1] - Otsuka previously held approximately 20.7% of the company's shares, selling 7.3% to Shanghai Shendi, 7.3% to We'Tron Capital Limited, and 1.1% to the management platform, retaining about 5% [1] - The entry of state-owned capital from Shanghai Shendi reflects recognition of the company's assets, potentially aiding core business expansion and strategic acquisitions while improving corporate governance [1] Business Performance - The company's core businesses are gradually recovering from the impact of centralized procurement, with expectations of price stabilization and new product contributions leading to revenue growth [2] - By July 2025, it is anticipated that most major products will have cleared the price reduction effects from centralized procurement, with a positive outlook on the penetration rate of minimally invasive procedures and domestic product localization [2] International Expansion - The company has a rich pipeline of cardiovascular and surgical robot products, demonstrating strong global competitiveness [2] - By the end of 2024, the company's products are expected to be in 40 major countries, supported by 20 mature overseas subsidiaries and 670 sales personnel, with projected overseas revenue of $9.6 million in 2024 and over 80% year-on-year growth in 2025 [2] Profit Forecast and Valuation - The profit forecasts for 2025 and 2026 remain unchanged, maintaining an outperform rating for the industry [2] - The target price has been raised by 54.5% to HKD 17 based on a DCF model, indicating a 31% upside potential from the current price [2]